showed a trendp = 0.0525
2 B), the Navax group showed a trend toward a 16% reduction in the rates of patients having this symptom at day 3 compared to day 0, approaching statistical significance ( p = 0.0525), while the Control group showed a smaller, non-significant 10% reduction ( p = 0.273).